Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy

Chronic kidney disease guidelines and disease modifying therapy have seen a dramatic shift in the last 5 years. The SGLT2 inhibitor class of medications has been catapulted from hyperglycemia management medications, to cardiovascular and kidney disease improvement therapies. Multiple trials looking...

Descripción completa

Detalles Bibliográficos
Autores principales: Colbert, Gates B, Madariaga, Hector M, Gaddy, Anna, Elrggal, Mohamed E, Lerma, Edgar V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901477/
https://www.ncbi.nlm.nih.gov/pubmed/36756278
http://dx.doi.org/10.2147/TCRM.S398163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901477/
https://www.ncbi.nlm.nih.gov/pubmed/36756278
http://dx.doi.org/10.2147/TCRM.S398163

Ejemplares similares